Everything below concerns Melanotan II. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Events in 1958 – notably a riot during Vice President Nixon's visit to Caracas, Venezuela, in May 1958 – resulted in a reversal of the U.S. position in August 1958. With U.S. support, in April 1959 the Organization of American States created the Inter-American Development Bank, most of whose capital was contributed by the borrowing countries. To further engage other wealthy countries in development assistance, the United States supported the creation of the Aid India Consortium in August 1958. This was the first of several informal groupings of donors focussing on particular countries. The United States also encouraged Western Europe and Japan to increase their development assistance by building on the European Marshall Plan organization, the Organization of European Economic Cooperation (OEEC). The OEEC had been created in 1948 by recipients of Marshall Plan aid, at the request of the United States government, to decide on allocation of that aid within Europe, and by the late 1950s it had fulfilled its original mandate. In January 1960, Eisenhower and Under Secretary of State C. Douglas Dillon got agreement from OEEC members to create a Development Assistance Group composed of the OEEC members who were the main sources of development assistance, along with non-members who were major donors – the U.S., Canada, and Japan. In 1961, the OEEC itself was restructured to become the Organisation for Economic Co-operation and Development, which established a Development Assistance Committee (DAC) as a restructured DAG that was brought under the OECD.
=== Australia === In Australia, the Therapeutics Goods Administration (TGA) considers preparations to be bioequivalent if the 90% confidence intervals (90% CI) of the rate ratios, between the two preparations, of Cmax and AUC lie in the range 0.80–1.25. Tmax should also be similar between the products. There are tighter requirements for drugs with a narrow therapeutic index and/or saturable metabolism – thus no generic products exist on the Australian market for digoxin or phenytoin for instance.
Ordinance No. 46 (full title: Abolition of the Provinces in the British Zone of the Former State of Prussia and Reconstitution thereof as Separate Länder), effective 23 August 1946, was an ordinance issued by the British Military Government (CCG/BE) in the British Zone of Allied-occupied Germany by which, among others, the Prussian Province of Schleswig-Holstein became the State of Schleswig-Holstein, and the Province of Hanover turned into the State of Hanover.
=== Use of Oriented Peptide Libraries to determine phosphopeptide binding specificity and protein kinase substrate specificity === In 1994, the Cantley lab published a novel strategy to determine the sequence specificity of phosphopeptide binding domains (initially SH2 domains). Subsequently, the oriented peptide library approach was extended to identify the substrate specificity of protein kinases toward synthetic peptides. This approach was then extended to characterize the specificity of Ser/Thr kinases and phospho-Ser/Thr binding domains. This approach was used to characterize the substrate specificity of a large number of protein kinases. The kinase specificity matrices generated from these experiments served as the basis for creating the website Scansite, allowing the de novo identification of candidate phosphorylation sites in an arbitrary protein. In later research, the oriented peptide library approach has also been used to characterize protease cleavage specificity. Modification of the original oriented peptide approach has allowed for large scale, kinome-wide determination of protein kinase specificity.
Sources: en.wikipedia.org
Meinhard I 1253–1258, also Count of Gorizia since 1231 Meinhard II 1258–1295, also Count of Gorizia until 1271, Duke of Carinthia and Margrave of Carniola from 1286, jointly with: Albert V 1258–1271, brother, also Count of Gorizia until 1304 Albert VI, son, until 1292 Henry II 1295–1335, son of Meinhard II, also Duke of Carinthia, King of Bohemia 1306 and 1307–1310, jointly with his brothers Louis, until 1305 Otto, until 1310 Male line extinct, Countess Margaret, daughter of Henry II, married to:
"A quick and simple introduction to Drosophila melanogaster". Drosophila Virtual Library. "Drosophila Genomics Resource Center" – collects, maintains and distributes Drosophila DNA clones and cell lines. "Bloomington Drosophila Stock Center" – collects, maintains and distributes Drosophila melanogaster strains for research "FlyBase—A Database of Drosophila Genes & Genomes". Archived from the original on November 3, 2018. Retrieved January 28, 2011. "NCBI Map Viewer – Drosophila melanogaster". Archived from the original on June 5, 2003. "Drosophila Virtual Library". "The Berkeley Drosophila Genome Project". "FlyMove". – video resources for Drosophila development "Drosophila Nomenclature—naming of genes". Archived from the original on October 8, 2011. View the Fruitfly genome on Ensembl View the dm6 genome assembly in the UCSC Genome Browser Manchester Fly Facility – for the public Archived 2015-05-13 at the Wayback Machine from the University of Manchester The droso4schools website with school-relevant resources about Drosophila Part 1 of the "Small fly: BIG impact" educational videos explaining the history and importance of the model organism Drosophila. Part 2 of the "Small fly: BIG impact" educational videos explaining how research is carried out in Drosophila. "Inside the Fly Lab"—broadcast by WGBH and PBS, in the program series Curious, January 2008. "How a Fly Detects Poison" Deprecated link archived 2013-01-13 at archive.today—WhyFiles.org article describes how the fruit fly tastes a larva-killing chemical in food.
== Fraudulent markets == A large number of services pretend to be a legitimate vendor shop, or marketplace of some kind in order to defraud people. These include the notoriously unreliable gun stores, or even fake assassination websites.
== H == hair cell - half-life - halobacteria - halotolerance - haploid - heat of fusion - heat of vaporization - heat shock protein - Hsp70 (70 kDa heat shock proteins) - Hsp90 (90 kDa heat shock proteins) - heavy-chain immunoglobulin - Hela cell - helminth protein - helper T cell - hemopexin - hemoglobin - herpes simplex virus protein vmw65 - heterocyclic compound - heterotroph - heterozygote - Hfr cell - Hill reaction - His tag - histamine H1 receptor - histamine H2 receptor - histamine receptor - histidine - histone - history of science and technology - HIV receptor - holoenzyme - homeobox - homeodomain protein - homology - homoserine - homozygote - homunculus - hormone - housekeeping gene - Human Genome Project - hybridization - hydrocarbon - hydrogen - hydrogen bond - hydrogenation - hydrogen-deuterium exchange - hydrolysis - hydrolytic enzyme - hydrophilic - hydrophobe - hydrophobic - hydrophobicity analysis - hydroxyl
Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder. Risk factors include a history of opioid misuse, current opioid misuse, young age, socioeconomic status, race, untreated psychiatric disorders, and environments that promote misuse (social, family, professional, etc.). Complications may include opioid overdose, suicide, HIV/AIDS, hepatitis C, and problems meeting social or professional responsibilities. Diagnosis may be based on criteria by the American Psychiatric Association in the DSM-5. Opioids include substances such as heroin, morphine, fentanyl, codeine, dihydrocodeine, oxycodone, hydrocodone, and tramadol. A useful standard for the relative strength of different opioids is morphine milligram equivalents (MME). It is recommended for clinicians to refer to daily MMEs when prescribing opioids to decrease the risk of misuse and adverse effects. Long-term opioid use occurs in about 4% of people following their use for trauma or surgery-related pain. In the United States, most heroin users begin by using prescription opioids that may also be bought illegally. People with opioid use disorder are often treated with opioid replacement therapy using methadone or buprenorphine.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.